{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:11:54Z","timestamp":1761862314697,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1016\/j.ahj.2003.07.019","type":"journal-article","created":{"date-parts":[[2003,12,22]],"date-time":"2003-12-22T16:48:52Z","timestamp":1072111732000},"page":"31-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices"],"prefix":"10.1016","volume":"147","author":[{"given":"Jose E","family":"Exaire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold L","family":"Dauerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J","family":"Topol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C","family":"Blankenship","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell E","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Moliterno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2003.07.019_BIB1","first-page":"228","article-title":"Immediate arterial hemostasis after cardiac catheterization","volume":"31","author":"Aker","year":"1994","journal-title":"Cathet Cardiovasc Diagn"},{"key":"10.1016\/j.ahj.2003.07.019_BIB2","first-page":"354","article-title":"Femoral arterial puncture management after percutaneous coronary procedures","volume":"13","author":"Duffin","year":"2001","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.ahj.2003.07.019_BIB3","first-page":"395","article-title":"Effectiveness and complications of vascular access closure devices after interventional procedures","volume":"12","author":"Sesana","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.ahj.2003.07.019_BIB4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0735-1097(02)01924-1","article-title":"Vascular closure devices in patients treated with anticoagulation and IIb\/IIIa receptor inhibitors during percutaneous revascularization","volume":"40","author":"Applegate","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2003.07.019_BIB5","first-page":"143","article-title":"Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro)","volume":"47","author":"Chamberlin","year":"1999","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2003.07.019_BIB6","first-page":"1","article-title":"Outcome of access site in patients treated with platelet glycoprotein IIb\/IIIa inhibitors in the era of closure devices","volume":"58","author":"Assali","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2003.07.019_BIB7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S0002-9149(99)00882-6","article-title":"Suture-mediated closure of the femoral access site after cardiac catheterization","volume":"85","author":"Baim","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2003.07.019_BIB8","first-page":"3","article-title":"Complications of femoral artery closure devices","volume":"52","author":"Carey","year":"2001","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2003.07.019_BIB9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0735-1097(01)01449-8","article-title":"Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices","volume":"38","author":"Dangas","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2003.07.019_BIB10","doi-asserted-by":"crossref","unstructured":"Cura FA, Kapadia SR, L'Allier PL, et al. Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb\/IIIa platelet blockade. Am J Cardiol 86:780\u20132","DOI":"10.1016\/S0002-9149(00)01081-X"},{"key":"10.1016\/j.ahj.2003.07.019_BIB11","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1067\/mhj.2000.110094","article-title":"A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement","volume":"140","author":"Moliterno","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2003.07.019_BIB12","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2003.07.019_BIB13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction","volume":"115","author":"Bovill","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2003.07.019_BIB14","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0002-9149(96)00386-4","article-title":"Low-normal or excessive body mass index","volume":"78","author":"Ellis","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2003.07.019_BIB15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0735-1097(02)01687-X","article-title":"The impact of body mass index on short- and long-term outcomes in patients undergoing coronary revascularization","volume":"39","author":"Hitinder","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2003.07.019_BIB16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0002-9149(02)02384-6","article-title":"Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox)","volume":"90","author":"Hitinder","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2003.07.019_BIB17","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0735-1097(98)00130-2","article-title":"Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide","volume":"31","author":"Mandak","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2003.07.019_BIB18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9149(97)00796-0","article-title":"Vascular access site complications after percutaneous coronary interventions with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial","volume":"81","author":"Blankenship","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2003.07.019_BIB19","first-page":"476","article-title":"Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials","volume":"57","author":"Blankenship","year":"2002","journal-title":"Cathet Cardiovasc Intervent"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870303006057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870303006057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T04:52:46Z","timestamp":1757566366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870303006057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0002870303006057"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2003.07.019","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2004,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2003.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}